Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Yousif Capital Management LLC

Yousif Capital Management LLC cut its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 4.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 37,043 shares of the company’s stock after selling 1,559 shares during the quarter. Yousif Capital Management LLC’s holdings in Neurocrine Biosciences were worth $5,056,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. State Street Corp increased its position in Neurocrine Biosciences by 11.7% during the 3rd quarter. State Street Corp now owns 5,148,293 shares of the company’s stock worth $593,186,000 after purchasing an additional 539,936 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Neurocrine Biosciences by 2.2% in the third quarter. Geode Capital Management LLC now owns 1,859,232 shares of the company’s stock worth $213,773,000 after acquiring an additional 39,610 shares in the last quarter. Braidwell LP increased its position in shares of Neurocrine Biosciences by 20.9% in the third quarter. Braidwell LP now owns 917,674 shares of the company’s stock worth $105,734,000 after acquiring an additional 158,665 shares in the last quarter. Jennison Associates LLC lifted its holdings in shares of Neurocrine Biosciences by 145.1% during the 4th quarter. Jennison Associates LLC now owns 820,694 shares of the company’s stock valued at $112,025,000 after acquiring an additional 485,894 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in Neurocrine Biosciences by 4.7% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 819,968 shares of the company’s stock worth $94,478,000 after purchasing an additional 37,098 shares during the period. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Neurocrine Biosciences Stock Performance

Shares of NASDAQ:NBIX opened at $150.51 on Friday. Neurocrine Biosciences, Inc. has a 1-year low of $110.95 and a 1-year high of $157.98. The company’s fifty day moving average is $138.41 and its two-hundred day moving average is $131.64. The stock has a market capitalization of $15.24 billion, a price-to-earnings ratio of 40.35 and a beta of 0.33.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Thursday, February 6th. The company reported $1.00 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 15.68% and a net margin of 17.21%. Sell-side analysts expect that Neurocrine Biosciences, Inc. will post 3.92 EPS for the current fiscal year.

Analysts Set New Price Targets

NBIX has been the topic of several research reports. Wedbush reissued an “outperform” rating and issued a $148.00 price objective on shares of Neurocrine Biosciences in a research report on Monday, December 16th. William Blair reiterated an “outperform” rating on shares of Neurocrine Biosciences in a report on Monday, December 16th. Barclays upped their price target on Neurocrine Biosciences from $160.00 to $165.00 and gave the stock an “overweight” rating in a report on Monday, December 23rd. Piper Sandler reiterated an “overweight” rating and set a $160.00 price objective on shares of Neurocrine Biosciences in a research note on Monday, December 23rd. Finally, Morgan Stanley upped their target price on shares of Neurocrine Biosciences from $170.00 to $185.00 and gave the company an “overweight” rating in a research note on Tuesday. Five analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $166.85.

Insider Activity at Neurocrine Biosciences

In related news, insider Julie Cooke sold 1,740 shares of Neurocrine Biosciences stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $152.89, for a total value of $266,028.60. Following the sale, the insider now directly owns 18,202 shares in the company, valued at $2,782,903.78. This trade represents a 8.73 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Ingrid Delaet sold 1,091 shares of the company’s stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $135.00, for a total transaction of $147,285.00. Following the completion of the transaction, the insider now owns 2,507 shares of the company’s stock, valued at approximately $338,445. This trade represents a 30.32 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 222,693 shares of company stock worth $32,718,279 in the last 90 days. 4.30% of the stock is currently owned by company insiders.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.